Clinical trial
Paclitaxel and Bryostatin 1 in Treating Patients With Advanced Pancreatic Cancer
NCT00031694 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00031694 |
|---|---|
| Title | Paclitaxel and Bryostatin 1 in Treating Patients With Advanced Pancreatic Cancer |
| Official title | A Phase II Study of Sequential Paclitaxel and Bryostatin-1 for Patients With Advanced Pancreatic Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer |
| Intervention type | Drug |
| Interventions | paclitaxel, bryostatin 1 |
| Enrollment | 19 |
| Start date | Mar 1, 2002 |
| Primary completion | Apr 1, 2010 |
| Completion | Apr 1, 2010 |
| First posted | Jan 27, 2003 |
| Last update posted | Jun 11, 2021 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: